Bone Biologics enters amended CEO agreement with $300K salary, transaction bonus provision

Bone Biologics Corp

CEO Jeffrey Frelick receives $300,000 annual base salary, bonus target of 50% of salary, and transaction bonus of 1-2% of deal value upon acquisition.
CFO Deina Walsh granted transaction bonus eligibility of 0.5-1% of deal value via amendment effective March 11, 2024.
Frelick's agreement renews automatically; severance includes one year base salary plus COBRA coverage for one year if terminated without cause.
Both agreements contain standard restrictive covenants and will be filed in the next quarterly report.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.